Analysts Issue Forecasts for Century Therapeutics, Inc.’s Q1 2025 Earnings (NASDAQ:IPSC)

Century Therapeutics, Inc. (NASDAQ:IPSC) – Research analysts at William Blair issued their Q1 2025 earnings estimates for shares of Century Therapeutics in a research note issued to investors on Thursday, April 11th. William Blair analyst S. Corwin expects that the company will post earnings per share of ($0.51) for the quarter. The consensus estimate for Century Therapeutics’ current full-year earnings is ($2.02) per share. William Blair also issued estimates for Century Therapeutics’ Q2 2025 earnings at $0.46 EPS, Q3 2025 earnings at $0.46 EPS, Q4 2025 earnings at $0.47 EPS and FY2025 earnings at $1.89 EPS.

IPSC has been the topic of a number of other research reports. HC Wainwright reissued a “buy” rating and set a $13.00 target price on shares of Century Therapeutics in a research report on Friday, March 15th. Piper Sandler reaffirmed an “overweight” rating and issued a $9.00 price objective (down previously from $10.00) on shares of Century Therapeutics in a research report on Friday. Finally, Canaccord Genuity Group lifted their price objective on shares of Century Therapeutics from $22.00 to $24.00 and gave the stock a “buy” rating in a research report on Friday, March 15th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $14.00.

Century Therapeutics Stock Performance

NASDAQ IPSC opened at $3.91 on Monday. The company has a market capitalization of $253.45 million, a price-to-earnings ratio of -1.71 and a beta of 1.33. The company’s 50-day simple moving average is $4.31 and its two-hundred day simple moving average is $3.07. Century Therapeutics has a one year low of $1.28 and a one year high of $5.51.

Century Therapeutics (NASDAQ:IPSC) last announced its quarterly earnings data on Thursday, March 14th. The company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.07. Century Therapeutics had a negative net margin of 6,115.12% and a negative return on equity of 54.73%. The company had revenue of $0.27 million during the quarter, compared to analyst estimates of $1.69 million.

Insiders Place Their Bets

In other Century Therapeutics news, insider Adrienne Farid sold 22,831 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $5.14, for a total transaction of $117,351.34. Following the sale, the insider now owns 114,149 shares of the company’s stock, valued at approximately $586,725.86. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last quarter, insiders have sold 25,509 shares of company stock valued at $127,635. Insiders own 7.60% of the company’s stock.

Institutional Trading of Century Therapeutics

Large investors have recently bought and sold shares of the stock. Citigroup Inc. lifted its stake in Century Therapeutics by 1,142.8% during the 2nd quarter. Citigroup Inc. now owns 8,339 shares of the company’s stock valued at $26,000 after acquiring an additional 7,668 shares during the period. UBS Group AG acquired a new stake in Century Therapeutics during the 4th quarter valued at approximately $28,000. Wells Fargo & Company MN lifted its stake in Century Therapeutics by 148.5% during the 2nd quarter. Wells Fargo & Company MN now owns 8,905 shares of the company’s stock valued at $28,000 after acquiring an additional 5,321 shares during the period. Barclays PLC lifted its stake in shares of Century Therapeutics by 533.3% in the 4th quarter. Barclays PLC now owns 5,408 shares of the company’s stock valued at $28,000 after purchasing an additional 4,554 shares during the period. Finally, Public Employees Retirement System of Ohio acquired a new position in shares of Century Therapeutics in the 1st quarter valued at $30,000. Hedge funds and other institutional investors own 50.20% of the company’s stock.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.